Lava Therapeutics Nv - Understand $lvtx stock

$LVTX Market Cap: $46.01 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$7.398M

TTM

Gross Margin

79.17%

TTM

Net Earnings

-$24.18M

TTM

Current Assets

$90.17M

Q2 2024

Current Liabilities

$14.11M

Q2 2024

Current Ratio

639.03%

Q2 2024

Total Assets

$92.28M

Q2 2024

Total Liabilities

$49.41M

Q2 2024

Book Value

$42.88M

Q2 2024

Cash

$35.09M

Q2 2024

P/E

-1.903

Nov 29, 2024 EST

Free Cash Flow

-$17.58M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019
Revenue	$6.769M	$19.39M	$5.000M	$3.190M	$0.00
YoY Change	-65.09%	287.82%	56.74%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019
Revenue	$6.769M	$19.39M	$5.000M	$3.190M	$0.00
Cost Of Revenue	$3.482M
Gross Profit	$3.287M	$19.39M	$5.350M
Gross Profit Margin	48.56%	100.0%	107.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019
Selling, General & Admin	$12.73M	$14.12M	$12.16M	$2.340M	$1.110M
YoY Change	-9.9%	16.15%	419.66%	110.81%
% of Gross Profit	387.16%	72.84%	227.29%
Research & Development	$33.81M	$40.11M	$37.19M	$13.64M	$7.470M
YoY Change	-15.69%	7.83%	172.68%	82.6%
% of Gross Profit	1028.72%	206.82%	695.2%
Depreciation & Amortization	$1.278M	$781.0K	$558.0K	$190.0K	$90.00K
YoY Change	63.64%	39.96%	193.68%	111.11%
% of Gross Profit	38.88%	4.03%	10.43%
Operating Expenses	$33.81M	$40.11M	$49.35M	$15.98M	$8.580M
YoY Change	-15.69%	-18.74%	208.84%	86.25%
Operating Profit	-$30.53M	-$20.71M	-$44.00M
YoY Change	47.37%	-52.93%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019
Interest Expense	$1.558M	$3.180M	-$837.0K	-$750.0K	-$90.00K
YoY Change	-51.01%	-479.93%	11.6%	733.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019
Pretax Income	-$41.70M	-$31.66M	-$45.19M	-$13.55M	-$8.680M
YoY Change	31.7%	-29.94%	233.51%	56.11%
Income Tax	$279.0K	$249.0K	$157.0K	$40.00K	$0.00
% Of Pretax Income
Net Earnings	-$41.97M	-$31.91M	-$45.35M	-$13.58M	-$8.680M
YoY Change	31.55%	-29.64%	233.92%	56.45%
Net Earnings / Revenue	-620.09%	-164.55%	-906.94%	-425.71%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.57	-$1.23	-$2.295M	-$535.7K	-$342.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019
Cash & Short-Term Investments	$95.57M	$132.9M	$133.2M	$12.88M	$6.540M
YoY Change	-28.07%	-0.25%	934.18%	96.94%
Cash & Equivalents
Short-Term Investments	$61.67M	$42.50M	$118.8M	$1.000M	$100.0K
Other Short-Term Assets	$1.627M	$4.411M	$2.568M	$760.0K	$60.00K
YoY Change	-63.11%	71.77%	237.89%	1166.67%
Inventory
Prepaid Expenses
Receivables	$1.459M	$3.254M	$363.0K	$930.0K	$60.00K
Other Receivables	$240.0K	$0.00	$371.0K	$270.0K	$140.0K
Total Short-Term Assets	$98.90M	$140.5M	$136.5M	$14.84M	$6.790M
YoY Change	-29.63%	2.95%	819.85%	118.56%
Property, Plant & Equipment	$2.494M	$2.083M	$1.946M	$1.220M	$1.020M
YoY Change	19.73%	7.04%	59.51%	19.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$319.0K	$809.0K	$796.0K	$630.0K	$30.00K
YoY Change	-60.57%	1.63%	26.35%	2000.0%
Total Long-Term Assets	$2.813M	$2.892M	$2.742M	$1.840M	$1.050M
YoY Change	-2.73%	5.47%	49.02%	75.24%
Total Assets	$101.7M	$143.4M	$139.2M	$16.68M	$7.840M
YoY Change
Accounts Payable	$4.446M	$3.965M	$2.553M	$760.0K	$380.0K
YoY Change	12.13%	55.31%	235.92%	100.0%
Accrued Expenses	$4.291M	$7.833M	$1.569M	$1.030M	$670.0K
YoY Change	-45.22%	399.24%	52.33%	53.73%
Deferred Revenue
YoY Change
Short-Term Debt	$5.282M	$4.640M	$0.00	$0.00	$0.00
YoY Change	13.84%
Long-Term Debt Due	$440.0K	$379.0K	$261.0K	$170.0K	$230.0K
YoY Change	16.09%	45.21%	53.53%	-26.09%
Total Short-Term Liabilities	$14.94M	$21.95M	$11.25M	$5.840M	$1.290M
YoY Change	-31.94%	95.18%	92.6%	352.71%
Long-Term Debt	$591.0K	$431.0K	$4.604M	$3.160M	$1.350M
YoY Change	37.12%	-90.64%	45.7%	134.07%
Other Long-Term Liabilities	$35.00M	$35.00M	$5.028M	$1.480M	$0.00
YoY Change	0.0%	596.1%	239.73%
Total Long-Term Liabilities	$35.59M	$35.43M	$9.632M	$4.640M	$1.350M
YoY Change	0.45%	267.85%	107.59%	243.7%
Total Liabilities	$50.53M	$57.39M	$20.88M	$10.48M	$2.630M
YoY Change	-11.94%	174.83%	99.24%	298.48%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $46.011 Million

About LAVA Therapeutics NV

LAVA Therapeutics NV is an immuno-oncology company. The company is headquartered in Utrecht, Utrecht and currently employs 37 full-time employees. The company went IPO on 2021-03-29. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Industry: Pharmaceutical Preparations Peers: Merus N.V. ProQR Therapeutics N.V. uniQure N.V.